Results 111 to 120 of about 5,279 (205)
Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic [PDF]
Journal of Pharmacy Practice and Research, 2022 Roberts, Jason A. +2 more
openaire +4 more sources
COVID-19 rebound after Paxlovid treatment [PDF]
Distributed via the CDC Health Alert NetworkMay 24, 2022, 9:00 AM ETCDCHAN-0467The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and ...
core
eLifePaxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients.
Zhanwei Du +8 more
doaj +1 more source
Paxlovid Awareness, Reporting Bias. [PDF]
Health affairs (Project Hope)Widera, Eric, Lee, Todd C, Prasad, Vinay
openaire +4 more sources
Québec authorizes pharmacists to prescribe Paxlovid
American Journal of Health-System Pharmacy, 2022 openaire +2 more sources
Nocebo Education and Behavioral Choice of Information about Paxlovid
This study will test the influence of nocebo education on the behavioral selection of Paxlovid side effect ...
Ananya Chatterjee +3 more
core +1 more source
Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
Kidney International Reports, 2022 Philipponnet, Carole +4 more
openaire +2 more sources
References pertaining to the potential impact of Paxlovid on PASC.
A compilation of references pertaining to the potential impact of Paxlovid on post-acute sequelae of SARS-CoV-2 infection (PASC)
Derakhshan, M
core +1 more source
Efficacy and Safety of Nirmatrelvir/Ritonavir and Molnupiravir in Non-Hospitalized Patients with COVID-19: A Single-Center Retrospective Study. [PDF]
Medicina (Kaunas)Pete M +5 more
europepmc +1 more source
Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol. [PDF]
CureusBactawar SB, Gaibor C, Abdul-Waheed M.
europepmc +1 more source